| Business Summary |
| A biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. |
| General Information |
3 North Dunlap Street
Van Vleet Bldg.
Memphis, TN 38163
|
| www.gtxinc.com |
| Industry : Drugs |
| Sector: Health Care |
| Employees: 147 |
| CEO: Dr. Mitchell S. Steiner, |
| Short Interest |
| Current Month (Mil) |
7.53 |
| Previous Month (Mil) |
8.38 |
| Short Interest Ratio (Days) |
5.80 |
| Management Effectiveness |
| Return on Equity |
n.a. |
| Return on Assets |
-75.70 |
| Return on Investments |
-205.00 |
| Profitability |
| Gross Margin |
n.a. |
| EBIT Margin |
n.a. |
| Profit Margin |
0.00 |
Connect with TheStreet